In spite of these somewhat contradictory results, we believe that SIRT1 and SIRT6 emerge as important targets for the development of novel therapies in the control of obesity and its comorbidities. This evidence concerns the gene SIRT1 and obesity due to melanocortin 4 receptor deficiency.